In human malignancy, the combination of immune checkpoint blockade and BCL-2 inhibition was seen to improve anti-tumor CD8 activity (68), suggesting that this combinatorial approach may also help improve anti-HIV immune function, though no studies have examined this combination to date. The gene discussed is CD8A; the disease is neoplasm.